| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
EG01449 (30 μM; pretreatment for 15 min) reduced VEGFA-induced phosphorylation of p38 in the retinal endothelium and hCMEC/D3[1]. EG01449 (30 μM; isolated rat lumbar DRG neurons) reduced the increase in sodium current induced by VEGFA165. EG01449 alone did not have a significant effect on Na+ current[1].
|
|---|---|
| ln Vivo |
EG01449 (10, 30 μM; plantar injection; single injection) significantly reduced VEGFA-induced mechanical phobia and VEGFA-induced mechanical and cold hyperalgesia in Sprague-Dawley [1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: Vascular endothelial cells of the ex vivo mouse retina and Human brain endothelial line hCMEC/D3 Tested Concentrations: 30 μM Incubation Duration: Preincubated for 15 min and then treated with VEGFA for 5 min. Experimental Results: VEGFA-induced phosphorylation of p38 phosphorylation was inhibited. |
| Animal Protocol |
Animal/Disease Models: Male and female rats (6 weeks old) were given an intraplantar injection in the hind-paw containing VEGFA165 (10 nM)[1]
Doses: 10 μM, 30 μM Route of Administration: Intraplantar injection; once Experimental Results: Significantly reduced VEGFA-induced mechanical allodynia in both male and female rats at 30 μM. At 10 μM, significant reduction in mechanical allodynia in males but not in females. Additionally, significantly reduced VEGFA-induced cold allodynia in females at 30 μM, but not at 10 μM. No significant effects were observed in females at 10 μM. Animal/Disease Models: Male and female rats (6 weeks old) were given an intraplantar injection in the hind-paw containing VEGFA165 (10 nM)[1] Doses: 10 μM, 30 μM Route of Administration: Intraplantar injection; once Experimental Results: Significantly reduced VEGFA-induced aversion to mechanical stimuli in both male and female rats at 30 μM. At 10 μM, significant reduction in aversion in males but not in females. No significant effects were observed in females at 10 μM. |
| References |
| Molecular Formula |
C29H36N10O7S3
|
|---|---|
| Molecular Weight |
732.85
|
| Related CAS # |
EG01449 Free acid
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3645 mL | 6.8227 mL | 13.6454 mL | |
| 5 mM | 0.2729 mL | 1.3645 mL | 2.7291 mL | |
| 10 mM | 0.1365 mL | 0.6823 mL | 1.3645 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
